FOLFOXIRI—improving outcomes of metastatic colorectal cancer

被引：0
|
作者：
Alessia Errico
机构：
来源：
Nature Reviews Clinical Oncology | 2014年 / 11卷 / 12期
关键词：
D O I：
10.1038/nrclinonc.2014.194
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：684 / 684
相关论文
共 50 条
  • [31] Geriatric factors and outcomes in metastatic colorectal cancer
    Papamichael, Demetris
    Aapro, Matti
    [J]. EUROPEAN JOURNAL OF CANCER, 2017, 74 : 96 - 97
  • [32] Outcomes in Metastatic Colorectal Cancer: Is Surgery Beneficial?
    Rana, M.
    Soosainathan, A.
    Dilke, S.
    Badiani, R.
    Holme, T.
    [J]. BRITISH JOURNAL OF SURGERY, 2015, 102 : 193 - 193
  • [33] Outcomes in Non-Metastatic Colorectal Cancer
    Smith, J. Joshua
    Weiser, Martin R.
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2014, 110 (05) : 518 - 526
  • [34] FOLFOXIRI plus biologics in advanced colorectal cancer
    Garcia-Alfonso, Pilar
    Torres, Gabriela
    Garcia, Gonzalo
    Gallego, Iria
    Ortega, Laura
    Sandoval, Carmen
    Munoz, Andres
    Lloansi, Ariadna
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (05) : 411 - 422
  • [35] Optimal Use of FOLFOXIRI Plus Bevacizumab as First-Line Systemic Treatment in Metastatic Colorectal Cancer
    Khatib, Jude
    Kainthla, Radhika
    [J]. CURRENT COLORECTAL CANCER REPORTS, 2020, 16 (04) : 89 - 95
  • [36] Use of FOLFOXIRI Plus Bevacizumab and Subsequent Therapies in Metastatic Colorectal Cancer: An Age-Stratified Analysis
    Vassilev, Zdravko P.
    Fan, Xiaozhou
    Xu, Julie
    Ostojic, Helene
    Barzi, Afsaneh
    [J]. CLINICAL COLORECTAL CANCER, 2024, 23 (03)
  • [37] Front-line use of FOLFOXIRI plus bevacizumab and subsequent therapies in metastatic colorectal cancer (mCRC).
    Barzi, Afsaneh
    Lunacsek, Orsolya
    Pisa, Federica
    Pan, Xiaoyun
    Ostojic, Helene
    Vassilev, Zdravko
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 45 - 45
  • [38] FOLFOXIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF BRAF MUTANT METASTATIC COLORECTAL CANCER PATIENTS
    Salvatore, Lisa
    Loupakis, Fotios
    Cremolini, Chiara
    Schirripa, Marta
    Masi, Gianluca
    Antoniotti, Carlotta
    Fornaro, Lorenzo
    Sensi, Elisa
    Lupi, Cristiana
    Bergamo, Francesca
    Lonardi, Sara
    Zagonel, Vittorina
    Fontanini, Gabriella
    Falcone, Alfredo
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 93 - 93
  • [39] A phase III comparison of FOLFOXIRI to FOLFIRI as first-line treatment of metastatic colorectal cancer (MCRC)
    Masi, G.
    Brunetti, I
    Murr, R.
    Benedetti, G.
    Evangelista, W.
    Picone, V
    Chiara, S.
    Merlano, M.
    Vitello, S.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 22 - 23
  • [40] Comparison of safety and efficacy of fluorouracil plus oxaliplatin plus irinotecan (FOLFOXIRI) and modified FOLFOXIRI with bevacizumab for metastatic colorectal cancer: data from clinical practice
    Kazama, Keisuke
    Shiozawa, Manabu
    Numata, Masakatsu
    Sugano, Nobuhiro
    Sato, Sumito
    Uchiyama, Mamoru
    Sato, Maho
    Aoyama, Toru
    Tamagawa, Hiroshi
    Oshima, Takashi
    Yukawa, Norio
    Rino, Yasushi
    [J]. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2022, 37 (02) : 337 - 348
12345